[{"address1": "9920 Pacific Heights Boulevard", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 704 4660", "website": "https://www.vikingtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00df), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00df for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 36, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian  Lian Ph.D.", "age": 58, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2023, "totalPay": 987100, "exercisedValue": 0, "unexercisedValue": 13998124}, {"maxAge": 1, "name": "Mr. Gregory S. Zante CPA, CPA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 655000, "exercisedValue": 0, "unexercisedValue": 59203}, {"maxAge": 1, "name": "Ms. Marianne  Mancini", "age": 59, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 670000, "exercisedValue": 0, "unexercisedValue": 2005070}, {"maxAge": 1, "name": "Mr. Michael  Morneau", "age": 59, "title": "Vice President of Finance & Administration", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 375333, "exercisedValue": 0, "unexercisedValue": 490518}, {"maxAge": 1, "name": "Dr. Geoffrey E. Barker Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 24.22, "open": 23.41, "dayLow": 21.5301, "dayHigh": 23.66, "regularMarketPreviousClose": 24.22, "regularMarketOpen": 23.41, "regularMarketDayLow": 21.5301, "regularMarketDayHigh": 23.66, "payoutRatio": 0.0, "beta": 0.831, "forwardPE": -14.980133, "volume": 6555242, "regularMarketVolume": 6555242, "averageVolume": 4474088, "averageVolume10days": 3722160, "averageDailyVolume10Day": 3722160, "bid": 21.19, "ask": 23.61, "bidSize": 1, "askSize": 1, "marketCap": 2539049728, "fiftyTwoWeekLow": 21.53, "fiftyTwoWeekHigh": 81.86, "fiftyDayAverage": 29.398, "twoHundredDayAverage": 49.008976, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1637552384, "profitMargins": 0.0, "floatShares": 109763765, "sharesOutstanding": 112248000, "sharesShort": 24214313, "sharesShortPriorMonth": 25107403, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.2157, "heldPercentInsiders": 0.027, "heldPercentInstitutions": 0.74246, "shortRatio": 4.34, "shortPercentOfFloat": 0.289, "impliedSharesOutstanding": 112248000, "bookValue": 7.89, "priceToBook": 2.8669202, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -109963000, "trailingEps": -1.01, "forwardEps": -1.51, "52WeekChange": -0.70189774, "SandP52WeekChange": -0.024663687, "quoteType": "EQUITY", "currentPrice": 22.62, "targetHighPrice": 164.0, "targetLowPrice": 38.0, "targetMeanPrice": 99.29412, "targetMedianPrice": 102.0, "recommendationMean": 1.52941, "recommendationKey": "buy", "numberOfAnalystOpinions": 17, "totalCash": 902611968, "totalCashPerShare": 8.041, "totalDebt": 1119000, "quickRatio": 32.926, "currentRatio": 33.094, "debtToEquity": 0.127, "returnOnAssets": -0.14774999, "returnOnEquity": -0.17899, "freeCashflow": -55577376, "operatingCashflow": -87790000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VKTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "epsTrailingTwelveMonths": -1.01, "epsForward": -1.51, "epsCurrentYear": -1.55224, "priceEpsCurrentYear": -14.572489, "fiftyDayAverageChange": -6.778, "fiftyDayAverageChangePercent": -0.23055989, "twoHundredDayAverageChange": -26.388975, "twoHundredDayAverageChangePercent": -0.53845185, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Buy", "cryptoTradeable": false, "regularMarketChangePercent": -6.6061044, "regularMarketPrice": 22.62, "corporateActions": [], "postMarketTime": 1743811196, "regularMarketTime": 1743796800, "shortName": "Viking Therapeutics, Inc.", "longName": "Viking Therapeutics, Inc.", "exchange": "NCM", "messageBoardId": "finmb_246791410", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1430227800000, "postMarketChangePercent": -2.69673, "postMarketPrice": 22.01, "postMarketChange": -0.610001, "regularMarketChange": -1.5999985, "regularMarketDayRange": "21.5301 - 23.66", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 4474088, "fiftyTwoWeekLowChange": 1.0900002, "fiftyTwoWeekLowChangePercent": 0.050627038, "fiftyTwoWeekRange": "21.53 - 81.86", "fiftyTwoWeekHighChange": -59.239998, "fiftyTwoWeekHighChangePercent": -0.72367454, "fiftyTwoWeekChangePercent": -70.18977, "earningsTimestamp": 1738789515, "earningsTimestampStart": 1745319540, "earningsTimestampEnd": 1745841600, "earningsCallTimestampStart": 1738791000, "earningsCallTimestampEnd": 1738791000, "isEarningsDateEstimate": true, "marketState": "CLOSED", "displayName": "Viking Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-04-05"}]